Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 6,616

Document Document Title
WO/2015/106025A1
The present invention relates to compounds including but not limited to of any one of formulas Ia, Ib, IIa, IIb, IIIa, IIIb, and IV to VI, VIIa, VIIb, VIIIa, VIIIb and VIIIc as described herein and their tautomers and/or pharmaceutically...  
WO/2015/066296A9
The instant invention provides near-infrared fluorescent nerve contrast agents and methods of using them.  
WO/2015/097475A1
The present invention relates to compounds of formula (I) shown below: wherein Q is as defined herein. The compounds of formula (I) act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The pr...  
WO/2015/095265A1
The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the p...  
WO/2015/095795A1
The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compo...  
WO/2015/095601A1
A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.  
WO/2015/094635A1
A curable resin composition containing a blend of multifunctional benzoxazines, and composite materials derived therefrom. The benzoxazine blend contains the combination of (A) a difunctional benzoxazine component and (B) a multifunction...  
WO/2015/095788A1
The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, Ra, Rb, Rc, Rd, Rg, and Cy are as defined herein. The invention also provides pharmaceutical compositio...  
WO/2015/095340A1
This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipi...  
WO/2015/088893A1
A corrosion-inhibiting composition includes a diluent and a mixture of organic salts of half ester-half acids of a dioic acid with of a glyceride group with a fatty acyl residue. Included are organic salts of glyceride-cyclic carboxylic ...  
WO/2013/177253A3
Disclosed are compounds having Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, m, and n are defined herein and methods of using the same.  
WO/2015/080183A1
A compound represented by general formula (1) is useful as a light-emitting material. In general formula (1), zero to one of R1 to R5 represents a cyano group, one to five of R1 to R5 independently represent a group represented by genera...  
WO/2015/067450A1
The invention relates to a method for producing amines, comprising the following steps: a. reacting a (i) carboxylic acid amide of general formula (I) or (ii) carboxylic acid diamide of general formula (II) or (iii) di-, tri-, or polypep...  
WO/2015/068770A1
 A method for producing carboxylic acid amide that obtains carboxylic acid amide by dehydrocondensation of carboxylic acid and amine, wherein arylboronic acid having an electron-attracting group at the meta position and/or para positio...  
WO/2015/066296A1
The instant invention provides near-infrared fluorescent nerve contrast agents and methods of using them.  
WO/2015/055447A1
The present invention relates to a process for preparing substituted isatoic acid anhydride compounds of the formula (I) in which R1 is Cl, Br, I, or CN; and R2 is CH3, Cl, Br; using anthranilic acid derivative compounds of formula (III)...  
WO/2015/042685A1
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhi...  
WO/2015/042397A1
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associat...  
WO/2015/034820A1
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowin...  
WO/2015/028409A1
The invention relates to selective estrogen receptor modulators (SERMs) and to methods for the preparation thereof, to the use thereof for the treatment and/or prophylaxis of disorders, and to the use thereof for producing medicaments fo...  
WO/2015/029354A1
[Problem] To provide a compound which emits fluorescence and delayed fluorescence as a material for a high efficiency organic electroluminescent element, and to further provide an organic photoluminescent element and a high efficiency, h...  
WO/2015/027058A2
Cycloalkyl amine compounds of Formula (I), wherein ring A is C3-C6 cycloalkyl, optionally substituted with one or more C1-C3 alkyl, and R5 is ORS2, in which RS2 is H or C1-C6 alkyl, or R5 and R6, together with the carbon atom to which th...  
WO/2015/025717A1
The objective of the present invention is to provide: a photoelectric conversion element which has excellent responsivity and high photoelectric conversion efficiency, and which can be produced by vapor deposition; and an optical sensor ...  
WO/2015/020553A1
The present invention provides carbazole compounds of the formula (I), which can be used for treating microbial, protozoan, viral infections and cancer.   
WO/2015/010626A1
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.  
WO/2015/012332A1
The present invention provides a therapeutic agent or a preventive agent for ophthalmic diseases caused by ocular neovascularization, the agent comprising as an active ingredient a morpholine compound represented by general formula (1) (...  
WO/2015/007630A1
The present invention relates to new salts, complexes, crystals, solutions, dispersions, and slurries of threonine-N,N-diacetic acid or derivatives thereof, to formulations containing those, to processes to prepare those, and to the use ...  
WO/2014/202589A1
The present invention relates to a process for manufacturing 4-propargylated amino- benzoxazinones of formula (I), comprising the following steps: step a) preparing propargyl chloride by reacting propargyl alcohol with thionyl chloride o...  
WO/2014/203840A1
A compound represented by general formula (1) is a red light-emitting material that has a high luminous efficiency. R1 to R8 each represent a hydrogen atom or a substituent group, at least one from among R1 to R8 being a group represente...  
WO/2014/200880A1
The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates t...  
WO/2014/193337A1
Disclosed are antioxidative, natural compounds, their salts, chelates and cleavage derivatives that exhibit a superior combination of properties. The compounds can be used for a variety of purposes, including stabilizing foods, cosmetics...  
WO/2014/193338A1
Disclosed are antioxidative natural compounds, their salts, chelates and cleavage derivatives that exhibit a superior combination of properties. The compounds can be used for a variety of purposes, including the stabilization of polymers...  
WO/2014/147182A3
The present invention relates to substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to inter...  
WO/2014/174745A1
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...  
WO/2014/175563A1
The present invention provides a method of preparing 4-(4-aminophenyl)-3-morpholinone, including the step of reducing 4-(4-nitrophenyl)-3-morpholinone by reacting sodium hydrosulfite (Na2S2O4) with 4-(4-nitrophenyl)-3-morpholinone. This ...  
WO/2014/168101A1
A compound represented by general formula (1) is useful as a luminescent material. R1-R10 represent hydrogen atoms or substituents, but at least one of R1-R10 is a group represented by general formula (2). R21-R30 represent hydrogen atom...  
WO/2014/159809A1
The present invention relates in part to a method of stabilizing chloropropenes, such as 1,1,2,3-tetrachloropropene, otherwise known to decompose and degrade, and to the resulting stabilized chloropropene, using a morpholine compound and...  
WO/2014/146752A1
The present application relates to a compound of a formula (I) which comprises a benzene group that is substituted with a group selected from carbazole derivatives and bridged amines and with an electron attracting group, wherein the two...  
WO/2014/142255A1
Provided is a heterocyclic compound exhibiting an RORγt-inhibiting action. Specifically provided is a compound represented by formula (I) or a salt thereof. [In the formula, Ar indicates partial formulas (1) through (5), Q indicates a b...  
WO/2014/145118A1
Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative di...  
WO/2014/142320A1
Provided is a compound represented by general formula (I) and capable of detecting lipid droplets and/or adipose tissue. (In formula (I), R1 represents a C1-4 alkyl group, R2 represents a C1-4 alkyl group, and X is a group represented by...  
WO/2014/138484A1
PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase ...  
WO/2014/137717A1
The present disclosure provides a curable composition containing a benzoxazine and a polysulfone-based toughener. The curable composition, upon curing, renders a cured article having well balanced thermal, chemical and mechanical propert...  
WO/2014/134341A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formu...  
WO/2014/130470A1
The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the tre...  
WO/2014/125410A1
The present invention provides N-substituted novel heterocyclic derivatives of formula (I) as protein kinase inhibitors, in which R1, R2 and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts the...  
WO/2014/097151A3
The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-d...  
WO/2014/115692A1
The purpose of the present invention is to provide a phthalocyanine compound which exhibits excellent light resistance and heat resistance and which is useful as a near-infrared absorbing agent. It was discovered that a phthalocyanine co...  
WO/2014/113467A1
Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer...  
WO/2014/110491A1
Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable...  

Matches 251 - 300 out of 6,616